Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Gilead’s HIV capsid inhibitor might need dosing only every six months
Studies indicate that there is a very low likelihood that people with HIV have preexisting resistance to the medication.
The investigational, injectable, long-acting antiretroviral is a potential new option for those with multidrug resistance.
An early trial of Gilead’s HIV capsid inhibitor supports three-month dosing.
The antiretroviral GS-6207 is injected under the skin and would need to be combined with other meds to fully suppress HIV.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.